Kraig Biocraft Laboratories Inc (KBLB)

[Eskaminagaga]

A buyout is not necessarily a good thing.

For example, Nexia Biotechnologies Inc. (the original spider-goat comapny) was trading at around CDN $1.75 just before the announcement about PharmAthene buying the company in 2005 with CDN $16.9 million going to the common stock shareholders. With only 23 million outstanding shares at the time, this equated to only CDN $0.72 per share, less than half of the value traded previously and less than the 52 week low at the time.

KBLB has 674 million outstanding shares. If the buyout for us were similar adjusting for inflation, it would be about $20 million going to shareholders, or only about $.03/share.

Now, granted, at the time Nexia was struggling with overwhelming debt, increasing company deficit, the inability to produce large quantities of protiens due to the long justation time for baby goats, inability to spin strong enough fiber from the proteins, and likely possibility that they had not achieved homozygosity with their goats.

I would hope that KBLB would be worth more than that with everything that Kim has accomplished thus far and i doubt Kim would sell so cheap at this time, but you never know. That is the risk that you have to take with stocks like this.